In this activity, we celebrate change! The three Archives articles featured in this activity describe new concepts and technologic advances that have gained in diagnostic utility and are impacting daily practice. Articles are from the Contributions from Emory University School of Medicine Special Section published in the March and April 2017 issues of Archives of Pathology & Laboratory Medicine.
The activity also includes an 18-item post-test written by article authors, Dr. Shiyong Li, Dr. Xiaoxian Lee, and Dr. Adeboye Osunkoya. The post-test checks your understanding of key points and contains brief case scenarios that allow you to apply article concepts.
The following articles are included in the activity:
- Shiyong Li, David L. Jaye, Kyle T. Bradley, Linsheng Zhang, Debra Saxe, George Deeb, Charlie E. Hill, and Karen P. Mann. Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. Archives of Pathology & Laboratory Medicine: March 2017, Vol. 141, No. 3, pp. 341-354.
- Xiaoxian Li, Gabriela M. Oprea-Ilies, and Uma Krishnamurti. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives of Pathology & Laboratory Medicine: April 2017, Vol. 141, No. 4, pp. 490-498.
- Carla L. Ellis, Lara R. Harik, Cynthia Cohen, and Adeboye O. Osunkoya. Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging. Archives of Pathology & Laboratory Medicine: April 2017, Vol. 141, No. 4, pp. 499-516.
After completing this SAM eligible activity and post-test, you should be able to:
- Identify the advantages and limitations of immunophenotypic and cytogenetic studies to accurately assess tissues of hematolymphoid neoplasms.
- Identify the genotypic studies used to subclassify hematolymphoid neoplasms, determine appropriate treatment, and monitor treatment response.
- Recognize the molecular and immunophenotypic characteristics of breast cancer subtypes, including subclassifications of triple-negative and claudin-low breast cancers.
- Describe the updated approach to assessing HER2/neu expression.
- Identify the important pathological features in evaluating breast cancer after neoadjuvant therapy.
- Recognize chromosomal aberrations associated with most translocation-associated renal cell carcinomas.
- Identify the translocation that is shared by both alveolar soft part sarcoma and translocation-associated renal cell carcinoma.
- Recognize the pathologic findings frequently associated with intraductal carcinoma of the prostate.
- Recognize the distinction between intraductal carcinoma of the prostate and high-grade prostatic intraepithelial neoplasia from the immunohistochemical standpoint.
- Indicate the percentage of patients with malignant pheochromocytomas and paragangliomas that harbor a germline SDHB mutation.
- Recognize the immunohistochemical profile associated with clear cell papillary (tubulopapillary) renal cell carcinoma.
- Specify the surgical option for prostate cancer with minimal post-operative recovery and blood loss.
- Recognize the histologic findings typically associated with cryotherapy.
Accreditation: The College of American Pathologists (CAP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Category 1: The College of American Pathologists designates this internet enduring material educational activity for a
maximum of 4.5
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Pathology’s (ABP) Maintenance of Certification (MOC) requirements for Self-Assessment Modules (SAMs).
Continuing Professional Development (CPD), Section 3 Credit
Accreditation in Canada: This event is an Accredited Self Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by the Canadian Association of Pathologists - Association Canadienne des Pathologistes. You may claim a maximum of 4.5 hours equivalent to 13.5 credits.
You have a total of three opportunities to take and pass the post-test. If you correctly answer 70% or more of the post-test items, you may claim credit. CME/SAM credit can be applied to the American Board of Pathology (ABP) Self-Assessment Module (SAM) requirements. The AMA requires that you pass the post-test in a enduring program to claim credit; therefore, if you do not pass, you cannot claim credit.
Attention Canadian Participants: You have three opportunities to take and pass the post-test. If you do not pass the post-test after three attempts, you may still claim CPD credit (self-assessment program credits) for this activity. Please contact a representative of the CAP Learning Division at 800-323-4040, option 1 or email@example.com with the name of this activity and the date completed to request a Letter of Participation.
To pay with a check, print a copy of this page and send it with your check to the address below. You will be notified when your payment has been processed and you have been registered into the activity.
College of American Pathologists
325 Waukegan Road
Northfield, IL 60093-2750
Refunds will be handled on an exception basis. Please submit your request to the CAP in writing via email at
firstname.lastname@example.org or fax at 847-832-8006.
Pop-up blockers must be turned off.
CAP Learning has recognized that some Veteran’s Administration, US Government, and military participants may have difficulty accessing the online assessment portion of this activity. If you experience difficulty or have any questions, please contact a representative of the CAP Learning Division at 800-323-4040, option 1 or email@example.com.
This activity and evaluation is available September 25, 2017 and will expire on September 24, 2020 12:00 AM (ET). You MUST claim credit by this date and time.